Literature DB >> 6171361

Myelin basic protein, oligoclonal bands, and IgG in cerebrospinal fluid as indicators of multiple sclerosis.

B Gerson, S R Cohen, I M Gerson, G H Guest.   

Abstract

There currently are three clinical laboratory procedures for use with cerebrospinal fluid that assist in the diagnosis of multiple sclerosis: measurement of myelin basic protein and IgG, and demonstration of an oligoclonal band. We compared characteristics of these procedures, using CSF samples from 166 patients identified as having (54 patients) or not having (112 patients) multiple sclerosis. We find that oligoclonal band demonstration is the most useful single test in helping to establish the presence of multiple sclerosis; IgG quantitation is the least helpful. Myelin basic protein should be quantitated for following the activity of multiple sclerosis; it may be applied only selectively in the context of screening. The incidence of false-positive results reinforces the view that the diagnosis of multiple sclerosis must be made in clinical context. These laboratory procedures are not suitable for use as screening tests.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6171361

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   12.167


  4 in total

1.  The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.

Authors:  K J Lamers; B M Uitdehaag; O R Hommes; W Doesburg; R A Wevers; W J von Geel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-10       Impact factor: 10.154

2.  An evaluation of cerebrospinal fluid oligoclonal banding confirmed by immunofixation on agarose gel.

Authors:  P M George; M A Lorier; I M Donaldson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-06       Impact factor: 10.154

3.  On the diagnostic value of different CSF investigations in multiple sclerosis.

Authors:  K Lauer
Journal:  J Neurol       Date:  1984       Impact factor: 4.849

Review 4.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.